BILINSKY IGOR 4

What Happened
Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics (IOVA), had 7,813 restricted stock units (RSUs) vest on June 5, 2026. The RSUs converted into 7,813 shares of common stock (reported as derivative exercise/conversion). The issuer withheld 3,976 shares to satisfy mandatory tax withholding at $4.23 per share (withheld value $16,818), leaving Bilinsky with a net 3,837 shares. The conversion/exercise carried no cash exercise price ($0).

Key Details

• Transaction date: 2026-06-05. Report filed 2026-06-09.
• Conversion/exercise: 7,813 RSUs → 7,813 shares (derivative code M). Exercise price reported $0.00.
• Tax withholding: 3,976 shares withheld (code F) at $4.23/share = $16,818; this is issuer withholding, not an open-market sale.
• Net shares received from this vesting: 3,837 shares (approx. $16,231 at $4.23/share). Total vested value ≈ $33,049.
• Footnotes: RSUs vested and converted to common stock (each RSU = 1 share). Remaining RSUs from the March 5, 2025 grant will vest in equal quarterly installments. The withholding is mandatory and not a public sale.

Context
This was an RSU vesting event and an administrative tax-withholding action — a routine insider transaction that does not indicate an open-market sale or purchase decision. The filing shows a conversion of RSUs into shares with shares withheld for taxes (cashless withholding), which is common when RSUs vest. There is no indication the filing was late.